Literature DB >> 26465984

Neonatal Glycemia and Neurodevelopmental Outcomes at 2 Years.

Christopher J D McKinlay1, Jane M Alsweiler, Judith M Ansell, Nicola S Anstice, J Geoffrey Chase, Gregory D Gamble, Deborah L Harris, Robert J Jacobs, Yannan Jiang, Nabin Paudel, Matthew Signal, Benjamin Thompson, Trecia A Wouldes, Tzu-Ying Yu, Jane E Harding.   

Abstract

BACKGROUND: Neonatal hypoglycemia is common and can cause neurologic impairment, but evidence supporting thresholds for intervention is limited.
METHODS: We performed a prospective cohort study involving 528 neonates with a gestational age of at least 35 weeks who were considered to be at risk for hypoglycemia; all were treated to maintain a blood glucose concentration of at least 47 mg per deciliter (2.6 mmol per liter). We intermittently measured blood glucose for up to 7 days. We continuously monitored interstitial glucose concentrations, which were masked to clinical staff. Assessment at 2 years included Bayley Scales of Infant Development III and tests of executive and visual function.
RESULTS: Of 614 children, 528 were eligible, and 404 (77% of eligible children) were assessed; 216 children (53%) had neonatal hypoglycemia (blood glucose concentration, <47 mg per deciliter). Hypoglycemia, when treated to maintain a blood glucose concentration of at least 47 mg per deciliter, was not associated with an increased risk of the primary outcomes of neurosensory impairment (risk ratio, 0.95; 95% confidence interval [CI], 0.75 to 1.20; P=0.67) and processing difficulty, defined as an executive-function score or motion coherence threshold that was more than 1.5 SD from the mean (risk ratio, 0.92; 95% CI, 0.56 to 1.51; P=0.74). Risks were not increased among children with unrecognized hypoglycemia (a low interstitial glucose concentration only). The lowest blood glucose concentration, number of hypoglycemic episodes and events, and negative interstitial increment (area above the interstitial glucose concentration curve and below 47 mg per deciliter) also did not predict the outcome.
CONCLUSIONS: In this cohort, neonatal hypoglycemia was not associated with an adverse neurologic outcome when treatment was provided to maintain a blood glucose concentration of at least 47 mg per deciliter. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others.).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26465984      PMCID: PMC4646166          DOI: 10.1056/NEJMoa1504909

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

1.  Neonatal morbidities and developmental delay in moderately preterm-born children.

Authors:  Jorien M Kerstjens; Inger F Bocca-Tjeertes; Andrea F de Winter; Sijmen A Reijneveld; Arend F Bos
Journal:  Pediatrics       Date:  2012-07-09       Impact factor: 7.124

2.  Continuous glucose monitoring in newborn babies at risk of hypoglycemia.

Authors:  Deborah L Harris; Malcolm R Battin; Philip J Weston; Jane E Harding
Journal:  J Pediatr       Date:  2010-03-24       Impact factor: 4.406

3.  Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit.

Authors:  Kupper A Wintergerst; Bruce Buckingham; Laura Gandrud; Becky J Wong; Saraswati Kache; Darrell M Wilson
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

4.  Cot-side electroencephalography monitoring is not clinically useful in the detection of mild neonatal hypoglycemia.

Authors:  Deborah L Harris; Philip J Weston; Christopher E Williams; Anthony B Pleasants; Malcolm R Battin; Claire G Spooner; Jane E Harding
Journal:  J Pediatr       Date:  2011-06-12       Impact factor: 4.406

Review 5.  Postnatal glucose homeostasis in late-preterm and term infants.

Authors:  David H Adamkin
Journal:  Pediatrics       Date:  2011-02-28       Impact factor: 7.124

6.  Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase.

Authors:  Sang Won Suh; Elizabeth T Gum; Aaron M Hamby; Pak H Chan; Raymond A Swanson
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

7.  Occipital lobe injury and cortical visual outcomes after neonatal hypoglycemia.

Authors:  Emily W Y Tam; Elysa Widjaja; Susan I Blaser; Daune L Macgregor; Prakash Satodia; Aideen M Moore
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

8.  Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia.

Authors:  Charlotte M Burns; Mary A Rutherford; James P Boardman; Frances M Cowan
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

9.  Short and long term outcome of neonatal hyperglycemia in very preterm infants: a retrospective follow-up study.

Authors:  N Margreth van der Lugt; Vivianne E H J Smits-Wintjens; Paul H T van Zwieten; Frans J Walther
Journal:  BMC Pediatr       Date:  2010-07-20       Impact factor: 2.125

10.  The impact of early hypoglycemia and blood glucose variability on outcome in critical illness.

Authors:  Sean M Bagshaw; Rinaldo Bellomo; Michael J Jacka; Moritoki Egi; Graeme K Hart; Carol George
Journal:  Crit Care       Date:  2009-06-17       Impact factor: 9.097

View more
  72 in total

1.  Paediatric endocrinology: Defining treatment thresholds for neonatal hypoglycaemia-how low is too low?

Authors:  Claire Greenhill
Journal:  Nat Rev Endocrinol       Date:  2015-11-03       Impact factor: 43.330

2.  Global motion perception is independent from contrast sensitivity for coherent motion direction discrimination and visual acuity in 4.5-year-old children.

Authors:  Arijit Chakraborty; Nicola S Anstice; Robert J Jacobs; Nabin Paudel; Linda L LaGasse; Barry M Lester; Trecia A Wouldes; Jane E Harding; Benjamin Thompson
Journal:  Vision Res       Date:  2015-09-02       Impact factor: 1.886

3.  Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.

Authors:  Suzanne N Landi; Sarah Radke; Stephanie M Engel; Kim Boggess; Til Stürmer; Anna S Howe; Michele Jonsson Funk
Journal:  JAMA Pediatr       Date:  2019-02-01       Impact factor: 16.193

4.  Cost Analysis of Treating Neonatal Hypoglycemia with Dextrose Gel.

Authors:  Matthew J Glasgow; Jane E Harding; Richard Edlin
Journal:  J Pediatr       Date:  2018-04-03       Impact factor: 4.406

Review 5.  Approach to hypoglycemia in infants and children.

Authors:  Kajal Gandhi
Journal:  Transl Pediatr       Date:  2017-10

Review 6.  Hypoglycemia in the preterm neonate: etiopathogenesis, diagnosis, management and long-term outcomes.

Authors:  Anudeepa Sharma; Ajuah Davis; Prem S Shekhawat
Journal:  Transl Pediatr       Date:  2017-10

7.  Maternal glycemic control in diabetic pregnancies and neurodevelopmental outcomes in preschool aged children. A prospective cohort study.

Authors:  Rebecca J Griffith; Jane E Harding; Christopher J D McKinlay; Trecia A Wouldes; Deborah L Harris; Jane M Alsweiler
Journal:  Early Hum Dev       Date:  2019-02-01       Impact factor: 2.079

8.  Global motion perception is associated with motor function in 2-year-old children.

Authors:  Benjamin Thompson; Christopher J D McKinlay; Arijit Chakraborty; Nicola S Anstice; Robert J Jacobs; Nabin Paudel; Tzu-Ying Yu; Judith M Ansell; Trecia A Wouldes; Jane E Harding
Journal:  Neurosci Lett       Date:  2017-08-31       Impact factor: 3.046

9.  Global motion perception is related to motor function in 4.5-year-old children born at risk of abnormal development.

Authors:  Arijit Chakraborty; Nicola S Anstice; Robert J Jacobs; Nabin Paudel; Linda L LaGasse; Barry M Lester; Christopher J D McKinlay; Jane E Harding; Trecia A Wouldes; Benjamin Thompson
Journal:  Vision Res       Date:  2017-04-28       Impact factor: 1.886

10.  Developmental Outcomes of Preterm Infants With Neonatal Hypoglycemia.

Authors:  Rachel H Goode; Mallikarjuna Rettiganti; Jingyun Li; Robert E Lyle; Leanne Whiteside-Mansell; Kathleen W Barrett; Patrick H Casey
Journal:  Pediatrics       Date:  2016-11-04       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.